Your browser doesn't support javascript.
loading
SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020-2023.
Yan, Yan; Ito, Kanami; Fukuda, Hiroshi; Nojiri, Shuko; Urasaki, Wataru; Yamamoto, Takamasa; Horiuchi, Yuki; Hori, Satoshi; Takahashi, Kazuhisa; Naito, Toshio; Tabe, Yoko.
Afiliação
  • Yan Y; Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Ito K; Department of Safety and Health Promotion, Juntendo University, Tokyo, Japan.
  • Fukuda H; Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Nojiri S; Department of Safety and Health Promotion, Juntendo University, Tokyo, Japan.
  • Urasaki W; Medical Technology Innovation Center, Juntendo University, Tokyo, Japan.
  • Yamamoto T; Clinical Research and Trial Center, Juntendo University, Tokyo, Japan.
  • Horiuchi Y; Graduate School of Science and Technology, Tokyo University of Science, Tokyo, Japan.
  • Hori S; Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan.
  • Takahashi K; Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Naito T; Infection Control Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Tabe Y; Department of Respiratory Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.
Hum Vaccin Immunother ; 20(1): 2337984, 2024 Dec 31.
Article em En | MEDLINE | ID: mdl-38622888
ABSTRACT
Infection-induced SARS-CoV-2 seroprevalence has been studied worldwide. At Juntendo University Hospital (JUH) in Tokyo, Japan, we have consistently conducted serological studies using the blood residue of healthcare workers (HCWs) at annual health examinations since 2020. In this 2023 study (n = 3,594), N-specific seroprevalence (infection-induced) was examined while univariate and multivariate logistic regression analyses were performed to compute ORs of seroprevalence with respect to basic characteristics of participants. We found that the N-specific seroprevalence in 2023 was 54.1%-a jump from 17.7% in 2022, and 1.6% in 2021-with 37.9% as non-PCR-confirmed asymptomatic infection cases. Those younger than 50 (adjusted OR = 1.62; p < .001) and recipients with 4 doses or less of vaccine had a higher risk to be N-positive, ranging from 1.45 times higher for the participants with 4 doses (p < .001) to 4.31 times higher for the participants with 1 dose (p < .001), compared to those with 5 or more doses. Our findings indicate that robust vaccination programs may have helped alleviate symptoms but consequently caused asymptomatic spread in this hospital, especially among younger HCWs. Although having four doses or less was found to be associated with higher risk of infection, the optimal constitution and intervals for effective booster vaccines warrant further investigations.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Idioma: En Ano de publicação: 2024 Tipo de documento: Article